Eurofins Scientific (ERFSF.PK), a provider of analytical testing and laboratory services, Wednesday reported revenue of 1.653 billion euros for the first quarter, 5 percent up from the same period last year, primarily driven by strong organic growth.
Adjusted for public working days, organic revenue growth in the core business, excluding COVID-19 related clinical testing and reagent revenues, was 6.8 percent.
For fiscal 2024, the company has reaffirmed its outlook. It still expects full-year revenue in the range of 7.075 billion euros - 7.175 billion euros. Adjusted earnings before interest, taxes, depreciation, and amortization or adjusted EBITDA for the year is now expected between 1.525 billion euros and 1.575 billion euros.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.